UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 22 von 2410
Datensatz exportieren als...
BibTeX
An MDS Evidence‐Based Review on Treatments for Huntington's Disease
Movement disorders, 2022-01, Vol.37 (1), p.25-35
Ferreira, Joaquim J.
Rodrigues, Filipe B.
Duarte, Gonçalo S.
Mestre, Tiago A.
Bachoud‐Levi, Anne‐Catherine
Bentivoglio, Anna Rita
Burgunder, Jean‐Marc
Cardoso, Francisco
Claassen, Daniel O.
Landwehrmeyer, G. Bernard
Kulisevsky, Jaime
Nirenberg, Melissa J.
Rosser, Anne
Roth, Jan
Seppi, Klaus
Slawek, Jaroslaw
Furr‐Stimming, Erin
Tabrizi, Sarah J.
Walker, Francis O.
Vandenberghe, Wim
Costa, João
Sampaio, Cristina
2022
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Ferreira, Joaquim J.
Rodrigues, Filipe B.
Duarte, Gonçalo S.
Mestre, Tiago A.
Bachoud‐Levi, Anne‐Catherine
Bentivoglio, Anna Rita
Burgunder, Jean‐Marc
Cardoso, Francisco
Claassen, Daniel O.
Landwehrmeyer, G. Bernard
Kulisevsky, Jaime
Nirenberg, Melissa J.
Rosser, Anne
Roth, Jan
Seppi, Klaus
Slawek, Jaroslaw
Furr‐Stimming, Erin
Tabrizi, Sarah J.
Walker, Francis O.
Vandenberghe, Wim
Costa, João
Sampaio, Cristina
Titel
An MDS Evidence‐Based Review on Treatments for Huntington's Disease
Ist Teil von
Movement disorders, 2022-01, Vol.37 (1), p.25-35
Ort / Verlag
Hoboken, USA: John Wiley & Sons, Inc
Erscheinungsjahr
2022
Quelle
MEDLINE
Beschreibungen/Notizen
ABSTRACT Background Huntington's disease (HD) is a rare neurodegenerative disorder with protean clinical manifestations. Its management is challenging, consisting mainly of off‐label treatments. Objectives The International Parkinson and Movement Disorder Society commissioned a task force to review and evaluate the evidence of available therapies for HD gene expansion carriers. Methods We followed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Eligible randomized controlled trials were identified via an electronic search of the CENTRAL, MEDLINE, and EMBASE databases. All eligible trials that evaluated one or more of 33 predetermined clinical questions were included. Risk of bias was evaluated using the Cochrane Risk of Bias tool. A framework was adapted to allow for efficacy and safety conclusions to be drawn from the balance between the GRADE level of evidence and the importance of the benefit/harm of the intervention. Results Twenty‐two eligible studies involving 17 interventions were included, providing data to address 8 clinical questions. These data supported a likely effect of deutetrabenazine on motor impairment, chorea, and dystonia and of tetrabenazine on chorea. The data did not support a disease‐modifying effect for premanifest and manifest HD. There was no eligible evidence to support the use of specific treatments for depression, psychosis, irritability, apathy, or suicidality. Similarly, no evidence was eligible to support the use of physiotherapy, occupational therapy, exercise, dietary, or surgical treatments. Conclusions Data for therapeutic interventions in HD are limited and support only the use of VMAT2 inhibitors for specific motor symptoms. © 2021 International Parkinson and Movement Disorder Society
Sprache
Englisch
Identifikatoren
ISSN: 0885-3185
eISSN: 1531-8257
DOI: 10.1002/mds.28855
Titel-ID: cdi_proquest_miscellaneous_2604466512
Format
–
Schlagworte
Apathy
,
Chorea
,
Clinical trials
,
drug therapy
,
Dystonia
,
Emotional behavior
,
evidence‐based medicine
,
GRADE approach
,
Humans
,
Huntingtin
,
Huntington Disease - drug therapy
,
Huntington Disease - therapy
,
Huntington's disease
,
Huntingtons disease
,
Movement disorders
,
Movement Disorders - drug therapy
,
Neurodegenerative diseases
,
Psychosis
,
Tetrabenazine
,
Tetrabenazine - therapeutic use
,
Therapeutic applications
,
Vesicular monoamine transporter 2
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX